VolitionRx Limited has announced the results of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa (HS), a chronic disease affecting approximately 1% of the global population. The Nu.Q® NETs assay, which is CE-Marked and commercially available in 27 EU member states, the EEA countries, and the U.K., is designed to detect diseases associated with NETosis. According to the company, the study supports the use of the assay to classify patients with HS and to serve as a surrogate marker for treatment response. The findings have been published and are available in JAMA Dermatology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN71844) on January 27, 2026, and is solely responsible for the information contained therein.